Antibody Persistence After a Primary Series of a New DTaP-IPV-Hep B-PRP-T Combined Vaccine or Separate DTaP-IPV//PRP-T and Hepatitis B Vaccines at 2, 4, and 6 Months of Age and the Effect of a Subsequent DTaP-IPV//PRP-T Booster Vaccination at 18 Months of Age in Healthy Argentinean Infants

Pediatric Infectious Disease Journal

Volumn 31, Issue 1, 2012, Pages e24-e30

  Tregnaghi, Marcelo ^a   Zambrano, Betzana ^a   Santos Lima, Eduardo ^a  

^a Centro de Desarrollo de Proyectos Avanzados Cordoba   (Argentina)

Author keywords

Booster vaccination; Multivalent; Pediatric; Persistence

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEMAGGLUTININ; HEPATITIS B VACCINE; PENTAXIM; PERTUSSIS TOXIN; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ANOREXIA; ANTIBODY BLOOD LEVEL; ARTICLE; BRONCHITIS; CHILD; CONVULSION; CRYING; DIARRHEA; ERYTHEMA; FEMALE; FEVER; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INJECTION SITE REACTION; IRRITABILITY; MALE; OPEN STUDY; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINITIS; SEROCONVERSION; SIDE EFFECT; SOMNOLENCE; SWELLING; VACCINATION; VOMITING;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; ARGENTINA; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; MALE; POLIOVIRUS VACCINE, INACTIVATED; TETANUS TOXOID; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 84855426980     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318242460a     Document Type: Article

References (24)

1. Decker M, Bogaerts H, Edwards K. Combination vaccines. In: Plotkin S, Orenstein W, Offit PA, eds. Vaccines. 5th ed. PA Saunders Co. 2008:1069-1101.
2. Edwards KM, Decker MD. Combination vaccines. Infect Dis Clin North Am. 2001;15:209-230.
3. World Health Organization. Pertussis position paper. Wkly Epidemiol Rec. 2010;85:385-400.
4. World Health Organization. The Children’s Vaccine Initiative and the Global Programme for Vaccines and Immunization. Recommendations from the Special Advisory Group of Experts. Part 1. Wkly Epidemiol Rec. 1997;72:237-243.
5. Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diptheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J. 2011;30:e88-e96.
6. Plotkin S, Liese J, Madhi SA, et al. A DTaP-IPV//PRP∼T vaccine (Pentaxim): a review of 16 years’ clinical experience. Expert Rev Vaccines. 2011;10:981-1005.
7. Diminsky D, Schirmbeck R, Reimann J, et al. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine. 1997;15:637-647.
8. Greiner VJ, Egele C, Oncul S, et al. Characterization of the lipid and protein organization in HBsAg viral particles by steady-state and time-resolved fluorescence spectroscopy. Biochimie. 2010;92:994-1002.
9. Milhiet PE, Dosset P, Godefroy C, et al. Nanoscale topography of hepatitis B antigen particles by atomic force microscopy. Biochimie. 2011;93:254-259.
10. Tregnaghi MW, Voelker R, Santos-Lima E, et al. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years. Vaccine. 2010;28:3595-3601.
11. Kosalaraska P, Thisyakorn U, Benjaponpitak S, et al. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, 6 months of age in Thai infants. Int J Infect Dis. 2011;15:e249-e256.
12. Madhi SA, Mitha I, Cutland C, et al. Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatr Infect Dis J. 2011;30:e68-e74.
13. Ceyhan M, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent fully liquid DTaP-IPV-Hep B-PRP-T vaccine given at 2, 3, 4 months of age with a booster at 15-18 months compared to licensed vaccines in Turkish infants [abstract]. In: 5th Asian Congress of Pediatric Infectious Diseases; September 23-26, 2010; Taipei, Taiwan.
14. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055-1065.
15. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857-872.
16. Carlsson RM, Claesson BA, Selstam U, et al. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J. 1998;17:1026-1033.
17. Li RC, Li FX, Li YP, et al. Antibody persistence at 18-20 months of age following primary vaccination of healthy infants with a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) and immunogenicity and safety of booster vaccination in the Peoples’ Republic of China [abstract]. In: 5th Asian Congress of Pediatric Infectious Diseases; September 23-26, 2010; Taipei, Taiwan. Vaccine. 2011;29:9337-9344.
18. Madhi SA, Cutland C, Jones S, et al. Post-primary vaccination antibody persistence and immunogenicity/safety of a DTaP-IPV//PRP∼T booster vaccine in South African infants aged 18 to 19 months [abstract]. In: 26th International Pediatric Association Congress of Pediatrics; August 4-9, 2010; Johannesburg, South Africa. SAMJ. in press.
19. WHO Expert Committee on Biological Standardization. Recommendations to assure the quality, safety and efficacy of recombinant hepatitis B vaccines. 2010. Available at: http://www.who.int/biologicals/BS2130_HEPB_Recomm_CLEAN.pdf. Accessed May 16, 2011.
20. World Health Organisation. Hepatitis B position paper. Wkly Epidemiol Rec. 2009;84:405-420.
21. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine. 2006;24:572-527.
22. Dutta A, Verghese VP, Pemde HK, et al. Post-primary vaccination antibody persistence and immunogenicity and safety of a DTaP-IPV//PRP∼T booster vaccination at 18 to 19 months of age in Indian infants [abstract]. In: 3th Asian Pacific Congress of Pediatrics; October 14-18, 2009; Shanghai, China.
23. Thisyakorn U, Pancharoen C, Chuenkitmongkol S, et al. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine. Southeast Asian J Trop Med Public Health. 2009;40:282-294.
24. Thisyakorn U, Chotpitayasunondh T, Pancharoen C, et al. Post-primary vaccination antibody persistence and immunogenicity/safety of a DTaP-IPV//PRP∼T booster at 18 to 19 months of age in Thai infants [abstract]. In: 6th Congress of the World Society for Pediatric Infectious Diseases; November 19-22, 2009; Buenos Aires, Argentina.